Becton Dickinson (BDX) Is Up 6.6% After Strong Q3 And Higher 2026 Outlook Has The Bull Case Changed?
Becton Dickinson (BDX) reported strong third-quarter fiscal 2026 results with increased sales, although net income fell year-over-year. The company raised its full-year 2026 guidance, expecting low single-digit GAAP revenue growth, driven by a more focused medical technology portfolio and new drug-delivery collaborations. Despite the …